Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
Abstract
Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles...
Paper Details
Title
Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
Published Date
Apr 1, 2020
Journal
Volume
16
Issue
12
Pages
749 - 762
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History